SABCS2016

Escalating Drug Prices Central to Value Discussion of Cancer Treatment Regimens

Escalating Drug Prices Central to Value Discussion of Cancer Treatment Regimens

By

In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.

Peer Navigation Program Helpful for Patients With Hereditary Cancers

Peer Navigation Program Helpful for Patients With Hereditary Cancers

By

Participants in a peer navigation program for patients at risk for HBOC were surveyed regarding the usefulness of the information provided, patient education, and their peer navigator. Survey results were presented at the 2016 SABCS.

MOCHA App Facilitates Communication Between Caregivers, Patients

MOCHA App Facilitates Communication Between Caregivers, Patients

By

An app developed to track posthospitalization progress and activity of patients with breast cancer, adding the information into patients' electronic health records in real time, was presented at SABCS 2016.

Scalp-cooling Device To Reduce Chemotherapy-related Alopecia

Scalp-cooling Device To Reduce Chemotherapy-related Alopecia

By

A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.

Menopause-related Nausea/Vomiting and Headaches Effects Tamoxifen Adherence

Menopause-related Nausea/Vomiting and Headaches Effects Tamoxifen Adherence

By

Women who experienced menopause-related side effects were significantly less likely to adhere to their assigned tamoxifen therapy.

Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women

Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women

By

A community breast navigation program successfully increased mammogram screening rates among African American and Latino women, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

Live-streamed Videos Address End-of-Life Planning, Decision-making

Live-streamed Videos Address End-of-Life Planning, Decision-making

By

Live-streamed videos are a novel and forward-thinking approach for individuals to learn about end-of-life (EOL) planning and decision-making, according a study presented at the 2016 San Antonio Breast Cancer Symposium.

Metastatic Disease Linked to Patients Reporting Diminished QoL

Metastatic Disease Linked to Patients Reporting Diminished QoL

By

Patients with metastatic breast cancer have significantly diminished quality of life (QoL) compared with those without metastatic disease and those without breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium.

History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis

History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis

By

A history of surgical menopause and were receiving hormone replacement therapy are a factor in breast density, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI

Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI

By

Study data presented at SABCS 2016 indicates that preoperative MRI is effective for detecting mammographically occult, early-stage, hormone receptor (HR)-positive contralateral breast cancer (CBC) in older patients.

Clinical Breast Examination Superior to MRI for Predicting pCR in HER2+ Breast Cancer

Clinical Breast Examination Superior to MRI for Predicting pCR in HER2+ Breast Cancer

By

Clinical breast examination (CBE) is superior to MRI for predicting pathologic complete response (pCR) in women with HER2-positive breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium indicates.

Genomic Features Predictive of Response to Trastuzumab-Containing Therapy

Genomic Features Predictive of Response to Trastuzumab-Containing Therapy

By

Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.

Video Tool to Increase Breast Cancer Clinical Trial Participation Among Black Women

Video Tool to Increase Breast Cancer Clinical Trial Participation Among Black Women

By

A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

No Difference Between RA Seed Localization and Wire Guided Localization

No Difference Between RA Seed Localization and Wire Guided Localization

By

Results of a comparison study of radioactive seed localization and wire guided localization in patients with nonpalpable invasive breast cancer or DCIS were presented at SABCS 2016.

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

By

Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.

BRD4 Inhibitor May Enhance Sensitivity to Endocrine Therapies

BRD4 Inhibitor May Enhance Sensitivity to Endocrine Therapies

By

A novel bromodomain-containing protein 4 inhibitor demonstrated antitumor activity in both endocrine-sensitive and endocrine-resistance breast cancer models, according to a study presented at SABCS 2016.

Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients

Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients

By

Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.

PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab

PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab

By

In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.

Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

By

In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.

Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer

Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer

By

Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.

Costs, Complications Higher for Women Who Undergo Second Surgery After BCS

Costs, Complications Higher for Women Who Undergo Second Surgery After BCS

By

A study presented at SABCS 2016 reports on the incidence of complications and costs in women who undergo breast-conserving surgery for breast carcinoma.

Omitting RT in Certain Older Women With Early Breast Cancer is Safe

Omitting RT in Certain Older Women With Early Breast Cancer is Safe

By

Researchers report their study findings on the safety of omitting radiotherapy after breast-conserving surgery, sentinel node biopsy, and adjuvant endocrine therapy in older patients with early breast cancer and favorable histopathology at SABCS 2016.

Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression

Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression

By

Researchers investigated the potential of PID fluorescent nanoparticles, a novel detection technique to visualize and quantify protein in clinical samples, for quantifying HER2 protein expression in breast cancer, according to a study presented at SABCS 2016.

Assessment of Stromal Features in DCIS Requires Robustness

Assessment of Stromal Features in DCIS Requires Robustness

By

Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.

RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy

RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy

By

Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.

Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers

Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers

By

Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.

In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS

In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS

By

In this study presented at SABCS 2016, investigators determined the association between higher TIL levels and overall survival in patients with advanced HER2-positive breast cancer treated with docetaxel plus trastuzumab in combination with pertuzumab or placebo.

High Immune Gene Expression Linked to Better Prognosis in TNBC

High Immune Gene Expression Linked to Better Prognosis in TNBC

By

Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.

Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer

Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer

By

Today at SABCS 2016 investigators presented results of the NRG Oncology/NSABP B-42, a double-blind phase 3 trial to determine whether extended treatment with letrozole would improve disease-free survival in certain women with HR-positive breast cancer.

Study Identifies Patients Who May Derive More Benefit From Veliparib

Study Identifies Patients Who May Derive More Benefit From Veliparib

By

At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs